1-11 of 11
Xiaoming Li
Close
Sort by
Journal Articles

Exploring the Impact of Humoral Immunogenicity with Tabelecleucel for the Treatment of EBV + PTLD Following HCT and SOT

Tassja J Spindler, Fiona Ruiz, Tiffany Jehng, Hanna Ding, Norma Guzman-Becerra, Shahram Khanzadeh, Xiaoming Li, Laurence Gamelin, Jason A. Dubovsky, Cokey Nguyen
Journal: Blood
Blood (2022) 140 (Supplement 1): 7529–7530.
https://doi.org/10.1182/blood-2022-157673
Published: 2022
Journal Articles

Exposure-Response of Idelalisib Administered in Combination with Ofatumumab for the Treatment of Relapsed Chronic Lymphocytic Leukemia

Shringi Sharma, PhD, Ying Guo, PhD, Feng Jin, PhD, Xiaoming Li, PhD, Ronald L. Dubowy, MD, Terry Newcomb, PhD, Srini Ramanathan, PhD
Journal: Blood
Blood (2015) 126 (23): 4172.
https://doi.org/10.1182/blood.V126.23.4172.4172
Published: 2015
Journal Articles

Exposure-Response Of Idelalisib, a Novel PI3Kδ Inhibitor, Administered As Monotherapy In The Treatment Of Hematologic Malignancies

Feng Jin, PhD, Huafeng Zhou, PhD, Lorna Fang, Xiaoming Li, PhD, Terry Newcomb, MD, Roger Dansey, MD, Srini Ramanathan, PhD
Journal: Blood
Blood (2013) 122 (21): 5054.
https://doi.org/10.1182/blood.V122.21.5054.5054
Published: 2013
Journal Articles

The Relative Bioavailability, Food Effect and Drug Interaction With Omeprazole Of Momelotinib Tablet Formulation

Yan Xin, PhD, Lixin Shao, MD MS, Wei Deng, PhD, Amanda Shaffer, Pharm D, Dimitrios Stefanidis, PhD, Jeffrey Hemenway, PhD, Xiaoming Li, PhD, Susie Jun, MD, PhD, Srini Ramanathan, PhD
Journal: Blood
Blood (2013) 122 (21): 5239.
https://doi.org/10.1182/blood.V122.21.5239.5239
Published: 2013
Journal Articles

Lysosomal Disruption Selectively Targets Leukemia Cells and Leukemia Stem Cells Through A Mechanism Related to Increased Reactive Oxygen Species Production

Mahadeo A. Sukhai, PhD, Rose Hurren, BSc, Angela Rutledge, PhD, Bozena Livak, Xiaoming Wang, Ayesh Seneviratne, Maria Christine Cusimano, Marinella Gebbia, PhD, Marko Skrtic, Hong Sun, Marcela Gronda, MSc, Paul A. Spagnuolo, PhD, Malene Urbanus, PhD, Kolja Eppert, PhD, Dilan Dissanayake, Xiaoming Li, PhD, Thomas Sun, Frederick Vizeacoumar, Alessandro Datti, PhD, Pamela Ohashi, PhD, FRSC, Jeff L. Wrana, PhD, Ian M. Rogers, PhD, Mark D. Minden, MD, PhD, Jean C.Y. Wang, MD, PhD, John E. Dick, PhD, Seth J. Corey, MD, Corey Nislow, PhD, Guri Giaever, PhD, Aaron D Schimmer, MD, PhD
Journal: Blood
Blood (2011) 118 (21): 61.
https://doi.org/10.1182/blood.V118.21.61.61
Published: 2011
Journal Articles

The Anti-Malarial Mefloquine Demonstrates Preclinical Activity In Leukemia and Myeloma, and Is Dependent Upon Toll-Like Receptor Signaling for Its Cytotoxicity

Mahadeo A. Sukhai, PhD, Xiaoming Li, PhD, Rose Hurren, Xiaoming Wang, Skrtic Marko, B.Sc., Hong Sun, Marcela Gronda, Ayesh Seneviratne, Dilan Dissanayake, Sue Chow, Rod Bremner, PhD, David Hedley, MD, Mark D. Minden, MD, PhD, Ohashi Pamela, PhD, FRSC, Aaron Schimmer, MD, PhD
Journal: Blood
Blood (2010) 116 (21): 290.
https://doi.org/10.1182/blood.V116.21.290.290
Published: 2010
Journal Articles

The ubiquitin-activating enzyme E1 as a therapeutic target for the treatment of leukemia and multiple myeloma

G. Wei Xu, Mohsin Ali, Tabitha E. Wood, Derek Wong, Neil Maclean, Xiaoming Wang, Marcela Gronda, Marko Skrtic, Xiaoming Li, Rose Hurren, Xinliang Mao, Meenakshi Venkatesan, Reza Beheshti Zavareh, Troy Ketela, John C. Reed, David Rose, Jason Moffat, Robert A. Batey, Sirano Dhe-Paganon, Aaron D. Schimmer
Journal: Blood
Blood (2010) 115 (11): 2251–2259.
https://doi.org/10.1182/blood-2009-07-231191
Published: 2010
Includes: Supplemental data
Journal Articles

The Novel Proteasome Inhibitor 5-Amino-8-Hydroxyquinole (5AHQ) Overcomes Bortezomib Resistance in Malignant Hematological Cell Line Models Harboring Mutations in the PSMB5 Gene.

Niels E Franke, MD, MSc, Johan van Meerloo, B.ASc, Linda Slot, MSc, Xiaoming Li, PhD, Tabitha E Wood, PhD, Katarina Vojtekova, MSc, Sue Ellen Verbrugge, MSc, Gertjan Kaspers, MD, PhD, Robert A. Batey, PhD, Aaron D. Schimmer, MD, PhD, Gerrit Jansen, PhD, Jacqueline Cloos, PhD
Journal: Blood
Blood (2009) 114 (22): 940.
https://doi.org/10.1182/blood.V114.22.940.940
Published: 2009
Journal Articles

A Novel Non-Competitive Chemical Proteasome Inhibitor Displays Preclinical Activity in Myeloma and Leukemia.

Xiaoming Li, PhD, Tabitha E Wood, PhD, Remco Sprangers, PhD, Xinliang Mao, PhD, Xiaoming Wang, PhD, Yi Zhang, BSc, David Rose, PhD, Robert A. Batey, PhD, Lewis E. Kay, PhD, Aaron D. Schimmer, MD, PhD
Journal: Blood
Blood (2008) 112 (11): 1711.
https://doi.org/10.1182/blood.V112.11.1711.1711
Published: 2008
Journal Articles

The Oral Off-Patent Antimicrobial Clioquinol Inhibits the Proteasome and Induces Cell Death in AML and Myeloma Cells through a Copper-Dependent Mechanism.

Xinliang Mao, PhD, Xiaoming Li, PhD, Rose Hurren, Bsc, Amudha Venugopal, PhD, Suzanne Trudel, MD, A. Keith Stewart, MD, Aaron D. Schimmer, MD, PHD
Journal: Blood
Blood (2007) 110 (11): 1595.
https://doi.org/10.1182/blood.V110.11.1595.1595
Published: 2007
Journal Articles

Phase IB Study of PKC412, an Oral FLT3 Kinase Inhibitor, in Sequential and Simultaneous Combinations with Daunorubicin and Cytarabine (DA) Induction and High-Dose Cytarabine Consolidation in Newly Diagnosed Adult Patients (pts) with Acute Myeloid Leukemia (AML) under Age 61.

Richard M. Stone, MD, Thomas Fischer, MD, Ronald Paquette, MD, Gary Schiller, MD, Charles A. Schiffer, MD, Gerhard Ehninger, MD, Jorge Cortes, MD, Hagop Kantarjian, MD, Daniel A. DeAngelo, MD, PhD, Georgio Massimini, MD, Xiaoming Li, PhD, Penny Phillips, PhD, Francis Giles, MD
Journal: Blood
Blood (2006) 108 (11): 157.
https://doi.org/10.1182/blood.V108.11.157.157
Published: 2006